On a relative basis, the stock has outperformed the S&P 500 by 2.66% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.2% in the last 1 week, and is up 5.21% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Zimmer Biomet Holdings (NYSE:ZBH): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $131.23 and $130.69 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $131.59. The buying momentum continued till the end and the stock did not give up its gains. It closed at $131.40, notching a gain of 0.37% for the day. The total traded volume was 758,127 . The stock had closed at $130.91 on the previous day.
The stock has recorded a 20-day Moving Average of 3.89% and the 50-Day Moving Average is 7.45%. Zimmer Biomet Holdings, Inc. is up 14.1% in the last 3-month period. Year-to-Date the stock performance stands at 28.64%.
Zimmer Biomet Holdings (ZBH) : The consensus price target for Zimmer Biomet Holdings (ZBH) is $136.38 for the short term with a standard deviation of $13.23. The most optimist securities analyst among the 16 who monitor the stock believes that the stock can reach $150, however, the pessimist price target for the company is $105.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.